SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

Whitehawk Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☑ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons ABG Management Ltd.
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 0.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 0.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 0 %
12		Type of Reporting Person (See Instructions) CO

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons Ally Bridge Group (NY) LLC
2		Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 0.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 0.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐

11	Percent of class represented by amount in row (9)	
	0 %	
12	Type of Reporting Person (See Instructions)	
	OO	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	
	Ally Bridge MedAlpha Master Fund L.P.	
2	Check the appropriate box if a member of a Group (see instructions)	
	☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization	
	CAYMAN ISLANDS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power	0.00
	6 Shared Voting Power	0.00
	7 Sole Dispositive Power	0.00
	8 Shared Dispositive Power	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
	0.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	☐	
11	Percent of class represented by amount in row (9)	
	0 %	
12	Type of Reporting Person (See Instructions)	
	PN	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	ABG Global Life Science Capital Partners V GP Limited
2	Check the appropriate box if a member of a Group (see instructions)

☐ (a)
☐ (b)

3 Sec Use Only

4 Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5 Sole Voting Power

0.00

6 Shared Voting Power

4,829,398.00

7 Sole Dispositive Power

0.00

8 Shared Dispositive Power

4,829,398.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

4,829,398.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐

11 Percent of class represented by amount in row (9)

7.8 %

12 Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No.

1 Names of Reporting Persons

ABG Global Life Science Capital Partners V GP, L.P.

2 Check the appropriate box if a member of a Group (see instructions)

☐ (a)
☐ (b)

3 Sec Use Only

4 Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5 Sole Voting Power

0.00

6 Shared Voting Power

4,829,398.00

7 Sole Dispositive Power

0.00

8 Shared Dispositive Power

		4,829,398.00
	Aggregate Amount Beneficially Owned by Each Reporting Person	
9		
	4,829,398.00	
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
10		
	☐	
	Percent of class represented by amount in row (9)	
11		
	7.8 %	
	Type of Reporting Person (See Instructions)	
12		
	PN	

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons	
1		
	Ally Bridge Group Global Life Science Capital Partners V, L.P.	
	Check the appropriate box if a member of a Group (see instructions)	
2		
	☐ (a) ☐ (b)	
3	Sec Use Only	
	Citizenship or Place of Organization	
4		
	CAYMAN ISLANDS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 4,829,398.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 4,829,398.00
	Aggregate Amount Beneficially Owned by Each Reporting Person	
9		
	4,829,398.00	
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
10		
	☐	
	Percent of class represented by amount in row (9)	
11		
	7.8 %	
	Type of Reporting Person (See Instructions)	
12		
	PN	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons ABG-SIV, L.P.	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization CAYMAN ISLANDS	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 4,829,398.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 4,829,398.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 4,829,398.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 7.8 %	
12	Type of Reporting Person (See Instructions) PN	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons ABG V-SIV Limited	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization CAYMAN ISLANDS	
Number of Shares Beneficially Owned by Each	5	Sole Voting Power 0.00
	6	Shared Voting Power

Reporting Person With:		4,829,398.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 4,829,398.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 4,829,398.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 7.8 %
12		Type of Reporting Person (See Instructions) CO

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons Fan Yu
2		Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization MALTA
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 4,829,398.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 4,829,398.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 4,829,398.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 7.8 %
12		Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Whitehawk Therapeutics, Inc.

(b) Address of issuer's principal executive offices:

2 Headquarters Plaza, East Building, 11th Floor, Morristown,NJ, 07960

Item 2.

(a) Name of person filing:

Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of: ABG Management Ltd. Ally Bridge Group (NY) LLC Ally Bridge MedAlpha Master Fund L.P. ABG Global Life Science Capital Partners V GP Limited ABG Global Life Science Capital Partners V GP, L.P. Ally Bridge Group Global Life Science Capital Partners V, L.P. ABG-SIV, L.P. ABG V-SIV Limited Mr. Fan Yu

(b) Address or principal business office or, if none, residence:

The principal business office address for Ally Bridge Group (NY) LLC is 430 Park Avenue, 12th Floor, New York, NY 10022. The principal business office address for ABG Management Ltd. and Mr. Fan Yu is Unit 3902, 39/F, East Tower Cheung Kong Center II, 10 Harcourt Road Central, Hong Kong. The principal business office address for each of the other Reporting Persons is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman, Cayman Islands.

(c) Citizenship:

Ally Bridge Group (NY) LLC is organized under the laws of the State of Delaware. Mr. Fan Yu is a citizen of Malta. Each of the other Reporting Persons is organized under the laws of the Cayman Islands.

(d) Title of class of securities:

Common Stock, par value $0.0001 per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

The information contained on the cover pages to this Schedule 13G is incorporated by reference into this Item 4. The ownership information presented herein represents beneficial ownership of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), based on 59,008,982 shares of Common Stock outstanding as of November 5, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission

on November 9, 2026. The amount of securities reported herein includes: (i) 1,619,472 shares of Common Stock held of record by ABG V-SIV Limited; and (ii) 3,209,926 shares of Common Stock issuable upon exercise of warrants held of record by ABG V-SIV Limited. The warrants are currently exercisable and are subject to a 9.99% beneficial ownership limitation on exercise. Ally Bridge MedAlpha Master Fund LP no longer holds shares in the Issuer. ABG Global Life Science Capital Partners V GP Limited is the general partner of ABG Global Life Science Capital Partners V GP, L.P., which is the general partner of each of Ally Bridge Group Global Life Science Capital Partners V, L.P. and ABG-SIV, L.P., which are the shareholders of ABG V-SIV Limited. Mr. Fan Yu is the controlling stockholder of ABG Global Life Science Capital Partners V GP Limited. Accordingly, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the securities held of record by ABG V-SIV Limited. Each of them disclaims beneficial ownership of such securities.

Percent of class:

(b)

See cover pages %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See cover pages

(ii) Shared power to vote or to direct the vote:

See cover pages

(iii) Sole power to dispose or to direct the disposition of:

See cover pages

(iv) Shared power to dispose or to direct the disposition of:

See cover pages

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ABG Management Ltd.

Signature: By: /s/ Fan Yu
Name/Title: Fan Yu, Director
Date: 11/16/2026

Ally Bridge Group (NY) LLC

Signature: By: ABG Management Ltd., its managing member, By: /s/ Fan Yu
Name/Title: Fan Yu, Director

Date: 11/16/2026

Ally Bridge MedAlpha Master Fund L.P.

Signature: By: Ally Bridge Group (NY) LLC, its manager, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu

Name/Title: Fan Yu, Director

Date: 11/16/2026

ABG Global Life Science Capital Partners V GP Limited

Signature: By: /s/ Shan-ju Yeh

Name/Title: Shan-ju Yeh, Director

Date: 11/16/2026

ABG Global Life Science Capital Partners V GP, L.P.

Signature: By: ABG Global Life Science Capital Partners V GP Limited, its general partner, By: /s/ Shan-ju Yeh

Name/Title: Shan-ju Yeh, Director

Date: 11/16/2026

Ally Bridge Group Global Life Science Capital Partners V, L.P.

Signature: By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Shan-ju Yeh

Name/Title: Shan-ju Yeh, Director

Date: 11/16/2026

ABG-SIV, L.P.

Signature: By: ABG Global Life Science Capital Partners V GP, L.P., ABG Global Life Science Capital Partners V GP Limited, /s/ Shan-ju Yeh

Name/Title: Shan-ju Yeh, Director

Date: 11/16/2026

ABG V-SIV Limited

Signature: By: /s/ Shan-ju Yeh

Name/Title: Shan-ju Yeh, Director

Date: 11/16/2026

Fan Yu

Signature: /s/ Fan Yu

Name/Title: Fan Yu

Date: 11/16/2026

Exhibit Information

Exhibit 99: Joint Filing Agreement (previously filed).